Is Lantus still in shortage in 2026? Get the latest update on Insulin Glargine availability, costs, alternatives, and how to find Lantus in stock near you.
If you depend on Lantus (Insulin Glargine) to manage your diabetes, the past year has been full of uncertainty. Reports of pharmacies running out of Insulin Glargine products have been popping up across the country, leaving patients scrambling to find their medication. Here's the latest on where things stand in 2026.
As of early 2026, brand Lantus is not in a formal FDA-listed shortage. Sanofi has confirmed that Lantus vials and SoloStar pens remain in production and are being distributed. However, the insulin glargine market as a whole has been disrupted.
The biggest factor: Biocon discontinued Semglee (Insulin Glargine-yfgn) on December 31, 2025. Semglee had been the most widely used biosimilar interchangeable with Lantus. Its disappearance created a wave of patients and insurance plans pivoting to brand Lantus and other Insulin Glargine products — putting new strain on the supply chain.
The result is a patchwork situation:
Several factors are contributing to the current availability challenges:
When a major biosimilar exits the market, demand doesn't disappear — it shifts. Millions of patients who were on Semglee needed to move to another Insulin Glargine product practically overnight. Insurance plans had to update formularies, and pharmacies had to adjust their ordering. This transition is still ongoing in early 2026.
Many insurance plans had Semglee as their preferred (or only covered) Insulin Glargine product. The switch to covering Lantus or Basaglar hasn't been smooth for everyone. Some patients face new prior authorization requirements, step therapy, or higher copays while their plans catch up.
With over 38 million Americans living with diabetes and the number continuing to grow, demand for all insulin products — including long-acting basal insulins like Lantus — keeps increasing.
For a deeper look at the reasons behind availability issues, read our full explainer on why Lantus is so hard to find.
One piece of good news: Lantus is significantly cheaper than it used to be. In 2023, Sanofi cut the list price of Lantus by 78%. Here's what patients can expect to pay in 2026:
For the full breakdown of savings options, check out our guide to saving money on Lantus.
The insulin landscape continues to evolve. In 2026, patients have more long-acting insulin choices than ever:
For a detailed comparison, read our guide on alternatives to Lantus.
If you need Lantus today, here's your action plan:
For more detailed strategies, see our post on how to find Lantus in stock near you.
The Lantus shortage situation in 2026 isn't a simple "in shortage" or "not in shortage" story. Brand Lantus is technically available, but disruptions in the broader Insulin Glargine market mean many patients are still running into problems at the pharmacy counter.
The best thing you can do is stay ahead of it: refill early, use tools like Medfinder to check stock, and know your alternatives. If you're dealing with side effects or drug interactions, our other guides can help you stay informed while you navigate these supply challenges.
You shouldn't have to worry about whether your insulin will be there when you need it. But until supply stabilizes, staying informed is your best protection.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
